Galecto Biotech AB-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Galecto Biotech AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011900
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Galecto Biotech AB (Galecto Biotech) is a biotech company that focuses on the development of novel drugs for the treatment of fibrosis, inflammation, and other diseases. The company’s products act against galectins or galactoside binding lectins, a group of proteins that are involved in various disease processes. Galecto Biotech developed a series of galectin modulators, which demonstrated efficacy in various disease models, including fibrosis, inflammation and cancer. Its pipeline products include TD139 for idiopathic pulmonary fibrosis; Gal-200 for ocular fibrosis; and galectin-3 inhibitors such as Gal-300 for non-alcoholic steatohepatitis (NASH) and fibrosis, and Gal-400 for immuno-oncology. Galecto Biotech AB is headquartered in Lund, Sweden.

Galecto Biotech AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Galecto Biotech AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Galecto Biotech Secures Venture Funding from SEED Capital 10
Galecto Biotech Raises Additional Funds In Seed Financing 11
Partnerships 12
Edinburgh BioQuarter Enters Into Co-Development Agreement With Galecto Biotech 12
Acquisition 13
Bristol-Myers Squibb Enters into Option to Acquire Galecto Biotech and TD-139 13
Galecto Biotech AB – Key Competitors 14
Galecto Biotech AB – Key Employees 15
Galecto Biotech AB – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Galecto Biotech AB, Pharmaceuticals & Healthcare, Key Facts 2
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Galecto Biotech AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Galecto Biotech AB, Deals By Therapy Area, 2011 to YTD 2017 8
Galecto Biotech AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Galecto Biotech Secures Venture Funding from SEED Capital 10
Galecto Biotech Raises Additional Funds In Seed Financing 11
Edinburgh BioQuarter Enters Into Co-Development Agreement With Galecto Biotech 12
Bristol-Myers Squibb Enters into Option to Acquire Galecto Biotech and TD-139 13
Galecto Biotech AB, Key Competitors 14
Galecto Biotech AB, Key Employees 15

★海外企業調査レポート[Galecto Biotech AB-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Securitas AB:企業の戦略・SWOT・財務分析
    Securitas AB - Strategy, SWOT and Corporate Finance Report Summary Securitas AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Amgen Inc (AMGN)-医療機器分野:企業M&A・提携分析
    Summary Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncol …
  • Telecom Plus plc (TEP):企業の財務・戦略的SWOT分析
    Telecom Plus plc (TEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Kyowa Hakko Kirin Co., Ltd.:企業の戦略・SWOT・財務情報
    Kyowa Hakko Kirin Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kyowa Hakko Kirin Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Mitsui Oil Exploration Co Ltd:企業の戦略的SWOT分析
    Mitsui Oil Exploration Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Reliance Worldwide Corporation Ltd (RWC):企業の財務・戦略的SWOT分析
    Reliance Worldwide Corporation Ltd (RWC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Frigo Pak Gida Maddeleri Sanayi ve Tic.:企業の戦略・SWOT・財務分析
    Frigo Pak Gida Maddeleri Sanayi ve Tic. - Strategy, SWOT and Corporate Finance Report Summary Frigo Pak Gida Maddeleri Sanayi ve Tic. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Biosynex SA (ALBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Biosynex SA (Biosynex), formerly All Diag Sarl is an in-vitro diagnostic company that manufactures, research, and develops rapid diagnostic tests. The company offers rapid diagnostic kits for diagnostic applications; and designing, self-measurement, and distributing thermometers. It offers t …
  • Shuttle Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Shuttle Pharmaceuticals Inc (Shuttle), formerly Shuttle Pharmaceuticals LLC is a developer of therapies that offers novel drugs for improving cancer treatment outcomes. The company’s pipeline products comprise therapies such as SP-2-001, SP-1-161, SP-1-003 and SP-3-001. Its therapies are use …
  • Tongaat Hulett Ltd:企業の戦略的SWOT分析
    Tongaat Hulett Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Radboud University Nijmegen Medical Centre-製薬・医療分野:企業M&A・提携分析
    Summary Radboud University Nijmegen Medical Centre (Radboud UMC), a subsidiary of Radboud University is a university medical center that offers patient care, research, and scientific training services. The centre’s patient care services include basic care, tertiary care, top referral care, and trans …
  • Cannabics Pharmaceuticals Inc (CNBX):製薬・医療:M&Aディール及び事業提携情報
    Summary Cannabics Pharmaceuticals Inc (Cannabics Pharmaceuticals), formerly Thrust Energy Corp, is a drug development company that develops cannabinoid-based therapies for cancer. The company develops High Content Screening (HCS) Platform, an automated cellular imaging and analysis platform designed …
  • Vestas Wind Systems AS (VWS):企業の財務・戦略的SWOT分析
    Vestas Wind Systems AS (VWS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • 3-D Matrix Ltd (7777):製薬・医療:M&Aディール及び事業提携情報
    Summary 3-D Matrix Ltd (3-D Matrix) is a regenerative medicine company that focuses at commercializing its self-assembling peptide technology. It develops medical products by applying this technology under a license granted by Massachusetts Institute of Technology (MIT). The technology finds applica …
  • AB-Biotics SA (ABB):製薬・医療:M&Aディール及び事業提携情報
    Summary AB-Biotics SA (AB-Biotics) is a provider of probiotics, pipeline products, specialty dietary supplements, and other functional ingredients. The company’s products comprise iron-containing ingredients, lactobacillus plantarum, probiotic products, gastrointestinal treatment products, proprieta …
  • Dalton Pharma Services-製薬・医療分野:企業M&A・提携分析
    Summary Dalton Pharma Services (Dalton) is a contract manufacturing company that offers discovery, development and contract manufacturing services. The company’s product categories include building blocks, coelenterazines, drugs and metabolites, glitazones, gmp APIs, excipients and reagents, heteroc …
  • Green Cross Cell Corp (031390):製薬・医療:M&Aディール及び事業提携情報
    Summary Green Cross Cell Corp (Green Cross Cell), a subsidiary of Green Cross Corp, is a provider of immunotherapeutics for the treatment of cancer. The company offers Immuncell-LC, an anti-cancer immune therapeutic that is derived from lymphocytes of cancer patient. It offers cryopreservation of co …
  • Delek US Holdings, Inc.:企業のM&A・事業提携・投資動向
    Delek US Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Delek US Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Nippon Shokubai Co Ltd (4114):企業の財務・戦略的SWOT分析
    Nippon Shokubai Co Ltd (4114) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • OPKO Health Inc (OPK):医療機器:M&Aディール及び事業提携情報
    Summary OPKO Health Inc (OPKO) discovers, develops, manufactures and commercializes novel diagnostic technologies and pharmaceuticals. The company’s product portfolio includes point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and proprietary pharmaceuticals and vac …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆